A resolution aimed at overturning President Biden's controversial nursing home staffing minimums has a chance of passing the Senate.
Why it matters: The vote would show the resistance to the first-of-its-kind standard and reveal a rift among Democrats, even though Biden would almost certainly veto the measure.
Major retailers are abandoning or scaling back their ambitions to become health care providers — but don't look for them to pull out of the market entirely.
Why it matters: Retailers hoping to grab a bigger piece of the $4.5 trillion health care market are likely to lean into their core strengths: consumer products, alongside some health services that don't require major investments, experts said.
Dan Buettner, the founder of the longevity-focused company Blue Zones, wants more people to live to 100.
Why it matters: Americans are spending a lot in their search for wellness, and Buettner's "secrets for living longer" don't require big bucks. In fact, one of his biggest health food hacks is eating beans.
A unanimous panel of federal drug advisers on Monday concluded that Eli Lilly's experimental Alzheimer's drug donanemab benefits patients with early stages of the disease and that its benefits outweigh its risks.
Why it matters: The pair of 11-0 votes could pave the way for the antibody to become the second drug of its kind to win Food and Drug Administration approval and concurrent Medicare coverage, based on evidence it can slow Alzheimer's progression by about a third.
Louisiana lawmakers approved a bill to remove the state's total ban on raw milk sales, joining the majority of the country where the product is already available, if and when Gov. Jeff Landry signs the legislation.
There are growing warningsabout a potent animal tranquilizer that's showing up in more of the illegal drug supply.
The big picture: Medetomidine has been linked to recent overdose deaths in the Midwest and Northeast, and is the latest example of how street drugs are becoming deadlier as more substances are mixed into illicit fentanyl and other opioids.
The outlook for the latest experimental drug shown to delay Alzheimer's disease will come into focus Monday, when Food and Drug Administration advisers review an application from Eli Lilly that's been held up by questions about the design of clinical trials and safety risks.
Why it matters: Their conclusions could influence how the FDA treats future drugs that target proteins in the brain known as amyloid plaques that are believed to contribute to the development of the dreaded neurological condition that afflicts nearly 7 million people in the U.S.
